8-K: Xencor Appoints Bart Cornelissen as New Chief Financial Officer

Xencor, a clinical-stage biopharmaceutical company, has appointed Bart Cornelissen as its new Senior Vice President and Chief Financial Officer, effective April 9, 2024.

Summary

• Xencor has appointed Bart Cornelissen as Senior Vice President and Chief Financial Officer, effective April 9, 2024.
• Mr. Cornelissen brings over 20 years of experience in corporate financial planning, analysis, and transaction support.
• Previously, he served as vice president, corporate finance at Seagen Inc., where he played a key role in the company's growth to over $2 billion in annual revenue and its $43 billion acquisition by Pfizer.
• Mr. Cornelissen's compensation includes an annual base salary of $465,000, a 45% discretionary bonus opportunity, and stock options and restricted stock units valued at approximately $3,250,000.
• Former CFO, John Kuch, retired from his role on March 31, 2024, and will transition to a non-executive capacity and consulting role.

Sentiment

Score: 8

Explanation: The document is positive due to the appointment of a highly qualified CFO with a strong track record. The transition appears smooth and well-planned, and the company's future outlook is optimistic.

Positives

• The appointment of Bart Cornelissen brings a seasoned financial executive with a strong track record to Xencor.
• Mr. Cornelissen's experience at Seagen, including its $43 billion acquisition by Pfizer, suggests he has expertise in scaling a company and managing significant transactions.
• His background at the Bill & Melinda Gates Foundation indicates experience in strategic financial decision-making and global health initiatives.
• The compensation package for Mr. Cornelissen is competitive and includes significant equity incentives, aligning his interests with the company's long-term success.

Risks

• The document includes standard forward-looking statements, which are subject to risks and uncertainties that could affect actual results.
• The success of Xencor's clinical-stage pipeline and the commercialization of its drug candidates are subject to various risks, including regulatory approvals and market acceptance.

Future Outlook

The company is focused on advancing its clinical-stage pipeline of drug candidates and exploring its XmAb platforms against novel biology. The new CFO is expected to support the company's growth and capitalization.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that Bart's exceptional track record in financial planning and analysis, business development and organizational excellence will be of great value to Xencor.
• Bart Cornelissen stated that he is pleased to join Xencor to support planning and capitalization for the company's growth, as its internal pipeline advances through clinical development.

Industry Context

This announcement is typical for a growing biopharmaceutical company that is transitioning from clinical development to potential commercialization. The appointment of an experienced CFO is a key step in this process.

Comparison to Industry Standards

• The compensation package for the new CFO is in line with industry standards for a company of Xencor's size and stage.
• The experience of the new CFO at Seagen, a company that was acquired for $43 billion, is a strong positive and is comparable to other successful biopharmaceutical companies.
• The transition of the previous CFO to a non-executive role is a common practice to ensure a smooth handover of responsibilities.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO with a strong track record as a positive development.
• Employees may be impacted by the change in leadership, but the transition appears to be well-managed.
• The appointment of a new CFO is unlikely to have a direct impact on customers or suppliers.

Next Steps

• Mr. Cornelissen will begin his role as CFO on April 9, 2024.
• Mr. Kuch will transition to a non-executive capacity and enter into a consulting agreement with the company at a later date.

Key Dates

Keywords

Chief Financial Officer, CFO, Xencor, Bart Cornelissen, executive appointment, biopharmaceutical, financial planning, Seagen, corporate finance, stock options, restricted stock units, executive compensation